419 related articles for article (PubMed ID: 26297092)
1. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
[TBL] [Abstract][Full Text] [Related]
2. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers.
Neumann PJ; Kuntz KM; Leon J; Araki SS; Hermann RC; Hsu MA; Weinstein MC
Med Care; 1999 Jan; 37(1):27-32. PubMed ID: 10413389
[TBL] [Abstract][Full Text] [Related]
3. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.
Neumann PJ; Sandberg EA; Araki SS; Kuntz KM; Feeny D; Weinstein MC
Med Decis Making; 2000; 20(4):413-22. PubMed ID: 11059474
[TBL] [Abstract][Full Text] [Related]
4. The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer's disease.
Wlodarczyk JH; Brodaty H; Hawthorne G
Arch Gerontol Geriatr; 2004; 39(1):25-33. PubMed ID: 15158578
[TBL] [Abstract][Full Text] [Related]
5. Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease.
Ready RE; Ott BR; Grace J
Int J Geriatr Psychiatry; 2004 Mar; 19(3):256-65. PubMed ID: 15027041
[TBL] [Abstract][Full Text] [Related]
6. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
7. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
[TBL] [Abstract][Full Text] [Related]
8. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
9. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD
J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
12. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.
Doraiswamy PM; Kaiser L; Bieber F; Garman RL
Alzheimer Dis Assoc Disord; 2001; 15(4):174-83. PubMed ID: 11723368
[TBL] [Abstract][Full Text] [Related]
13. Psychometric properties of the Dependence Scale in large randomized clinical trials of patients with mild and moderate Alzheimer's disease.
Wyrwich KW; Auguste P; Buchanan J; Rudell K; Lacey L; Leibman C; Symonds T; Brashear HR
Am J Alzheimers Dis Other Demen; 2014 Nov; 29(7):620-9. PubMed ID: 24736801
[TBL] [Abstract][Full Text] [Related]
14. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.
Bilikiewicz A; Gaus W
J Alzheimers Dis; 2004 Feb; 6(1):17-26. PubMed ID: 15004324
[TBL] [Abstract][Full Text] [Related]
15. Association Between Self- and Proxy-Reported Depression and Quality of Life in Mild-Moderate Alzheimer's Disease.
Joe E; Segal-Gidan F; Cummings JL; Galasko D; Tomaszewski Farias S; Johnson DK; Ross L; Yaffe K; Wang X; Schneider LS; Chui H; Ringman JM;
Am J Geriatr Psychiatry; 2024 Jan; 32(1):58-67. PubMed ID: 37827916
[TBL] [Abstract][Full Text] [Related]
16. Inter-rater agreement of the Quality of Life-Alzheimer's Disease (QoL-AD) self-rating and proxy rating scale: secondary analysis of RightTimePlaceCare data.
Römhild J; Fleischer S; Meyer G; Stephan A; Zwakhalen S; Leino-Kilpi H; Zabalegui A; Saks K; Soto-Martin M; Sutcliffe C; Rahm Hallberg I; Berg A;
Health Qual Life Outcomes; 2018 Jun; 16(1):131. PubMed ID: 29954384
[TBL] [Abstract][Full Text] [Related]
17. Use of the QOL-AD for measuring quality of life in people with severe dementia--the LASER-AD study.
Hoe J; Katona C; Roch B; Livingston G
Age Ageing; 2005 Mar; 34(2):130-5. PubMed ID: 15713856
[TBL] [Abstract][Full Text] [Related]
18. The relationship between caregivers' global ratings of Alzheimer's disease patients' quality of life, disease severity, and the caregiving experience.
Karlawish JH; Casarett D; Klocinski J; Clark CM
J Am Geriatr Soc; 2001 Aug; 49(8):1066-70. PubMed ID: 11555068
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychiatric symptoms and quality of life in Alzheimer disease.
Shin IS; Carter M; Masterman D; Fairbanks L; Cummings JL
Am J Geriatr Psychiatry; 2005 Jun; 13(6):469-74. PubMed ID: 15956266
[TBL] [Abstract][Full Text] [Related]
20. Assessing outcomes in Alzheimer disease.
Schneider LS
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S8-18. PubMed ID: 11669509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
